Abstract:Background: Uricase, or urate oxidase (Uox) is a key enzyme in uric acid (UA) metabolism and has been applied in clinical treatment of human hyperuricemia (HUA). However, the current clinically applied uricases, despite their potent urate-lowering capacity, tend to form anti-drug antibodies because of their immunogenicity, leading to increased risk of anaphylaxis, faster drug clearance and reduced or even complete loss of therapeutic effect, limiting their clinical application. In this study, we constructed engineered macrophages that stably expressed uricase, which might serve as a promising alternative to the direct injection of uricases. Materials and Methods: Engineered macrophages RAW264.7 cells were injected intravenously to treat hyperuricemic KM mice. Serum uric acid and bio-indicators for renal and hepatic functions were detected by an automatic biochemical analyzer; inflammatory cytokines were determined by ELISA; the livers and kidneys of the mice were sectioned for histological examination. Results: The uricase-expressing macrophages reduced UA levels from 300 ± 1.5 μmol/L to 101 ± 8.3 μmol/L in vitro. And in an HUA mouse model established by gavage with yeast extract, intravenous injection of the engineered macrophages could reduce the serum uric acid (sUA) of mice to normal level on the 14th day of modeling, with a decrease of 48.6%, and the urate-lowering effect was comparable to that of the first-line clinical drug allopurinol. In terms of safety, engineered macrophages did not cause liver or kidney dysfunction in mice, nor did they induce systemic immune response. Conclusions: Using macrophages as a chassis to deliver uricase might be a new, safe and effective strategy for the treatment and control of hyperuricemia.

Soluble Expression of Bioactive Recombinant Porcine-Human Chimeric Uricase Mutant Employing MBP-SUMO Fusion System.

Rationalization design, soluble expression and PEG modification of highly active recombinant human-porcine uricase mutant protein

A Novel Zwitterionic Copolymer with A Short Poly(Methyl Acrylic Acid) Block for Improving Both Conjugation and Separation Efficiency of A Protein Without Losing Its Bioactivity

PEGylated porcine–human recombinant uricase: A novel fusion protein with improved efficacy and safety for the treatment of hyperuricemia and renal complications

Construction,expression and Characterization of Recombinant Fusion Protein HSA-PTH(1-34) in Pichia Pastoris

Identification of key areas for Aedes aegypti control through geoprocessing in Nova Iguaçu, Rio de Janeiro State, Brazil.

Process for Production of Recombinant Baboon Uricase in Escherichia Coli Rosetta (DE3)

Uricase-Expressing Engineered Macrophages Alleviate Murine Hyperuricemia

Functional Expression of Hepassocin in Escherichia Coli Using SUMO Fusion Partner and Molecular Chaperones.

Soluble expression, rapid purification, and characterization of human interleukin-24 (IL-24) using a MBP-SUMO dual fusion system in Escherichia coli

Expression and purification of human urodilatin by small ubiquitin-related modifier fusion in Escherichia coli

Efficient purification of a recombinant tag-free thermostable Kluyveromyces marxianus uricase by pH-induced self-cleavage of intein and expression in Escherichia coli

EFFICIENT PRODUCTION OF URIDINE 5′-DIPHOSPHO-N-ACETYLGLUCOSAMINE BY THE COMBINATION OF THREE RECOMBINANT ENZYMES AND YEAST CELLS

Craniotomy unplugged

Integrate Thermostabilized Fusion Protein Apocytochrome B 562 RIL and N-glycosylation Mutations: A Novel Approach to Heterologous Expression of Human UDP-glucuronosyltransferase (UGT) 2B7.

Engineering of a Pichia pastoris Expression System for High-Level Secretion of HSA/GH Fusion Protein

High-yield expression, purification, characterization, and structure determination of tag-free Candida utilis uricase

Engineered Escherichia coli Nissle 1917 with urate oxidase and an oxygen-recycling system for hyperuricemia treatment

Engineering Bifunctional Galactokinase/Uridyltransferase Chimera for Enhanced UDP-d-Xylose Production

Immunogenicity-masking delivery of uricase against hyperuricemia and gout

Application of SUMO fusion technology for the enhancement of stability and activity of lysophospholipase from Pyrococcus abyssi